Medical cannabis in older adults: real-world evidence from a retrospective observational study
This retrospective observational study of 124 older adults in Colombia demonstrates that physician-supervised medical cannabis treatment is associated with significant symptom improvement, low effective doses, and an acceptable safety profile with no serious adverse events, suggesting it may be a viable therapeutic option for selected elderly patients.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, the medical community has faced a quiet dilemma: how to treat the complex, overlapping health issues of older adults without piling on more pills. As people age, they often accumulate multiple chronic conditions, from persistent pain and sleeplessness to mood disturbances and neurological decline. This reality frequently leads to "polypharmacy," a state where a patient takes five or more different medications daily, increasing the risk of dangerous interactions and side effects. In this crowded landscape, doctors have increasingly looked toward medical cannabis, a plant-based therapy that interacts with the body's natural signaling system to regulate pain, sleep, and mood. However, the scientific evidence for its use in the elderly has been thin. Older adults are rarely included in the strict, controlled clinical trials that usually define medical standards, partly because researchers worry that aging bodies might react unpredictably to the plant's active compounds. This leaves a gap in knowledge: while many older patients are turning to cannabis in real-world clinics, there is little data to confirm whether it helps them safely or if it simply adds another layer of risk to their fragile health.
To fill this gap, a team of researchers in Colombia and Spain conducted a close look at the actual experiences of older adults receiving supervised medical cannabis in routine care. They did not run a new experiment where they assigned patients to different treatments; instead, they acted as careful observers, reviewing the medical records of 124 people aged 65 and older who had started treatment at a specialized clinic between early 2024 and late 2025. The study focused on two groups: everyone who started treatment to understand who these patients were, and a smaller group of 44 patients who stayed in care long enough to be checked at least three months later. The goal was to see how their symptoms changed, what doses worked, whether they had to stop taking other medicines, and if the treatment caused any harm.
The patients in this group represented the typical complexity of geriatric care. The median age was 74, and more than two-thirds were women. They were not there for a single issue but for a web of problems. The most common reasons for seeking treatment were pain, trouble sleeping, and mood or behavioral changes, often occurring alongside conditions like cancer, arthritis, or neurodegenerative diseases. At the start, most of these patients were already taking a median of five different prescription drugs, a clear sign of the heavy medication burden they carried. When doctors began the cannabis treatment, they did not use a one-size-fits-all approach. Instead, they started with very low doses of standardized oil-based formulations, carefully adjusting the amount based on how each person responded. The active ingredients used included THC, CBD, and CBG, often in balanced combinations, but the amounts prescribed were consistently small, usually just a few milligrams per day.
Over the course of the follow-up period, the results painted a picture of gradual, meaningful improvement. Among the patients who were followed for at least three months, the severity of their main symptoms dropped significantly. Pain, insomnia, and mood issues shifted from a moderate level of distress to a mild one for the vast majority of people. In fact, about 90 percent of the patients saw at least a noticeable reduction in their worst symptom. This improvement was not a sudden cure; complete disappearance of symptoms was rare. Instead, the treatment seemed to lower the burden of suffering, making daily life more manageable. The researchers noted that this pattern of partial relief rather than total elimination is often the realistic goal when managing chronic conditions in older age.
Safety was a primary concern, given the fears that cannabis might cause confusion, dizziness, or falls in the elderly. The study found that while about one-third of the patients experienced some side effect, these were almost always mild or moderate. The most common complaints were sleepiness and dizziness, which typically appeared early in the treatment as the body adjusted to the new medicine. Crucially, the researchers recorded no serious adverse events, no falls, and no hospitalizations linked to the treatment. The side effects tended to fade as the treatment continued, with no new issues reported after the sixth visit. This suggests that with careful monitoring and slow dose adjustments, the therapy can be tolerated well even by those with complex health needs.
Another significant finding concerned the other medications these patients were taking. While the total number of drugs in the group did not change dramatically, a subset of patients was able to reduce or stop taking specific medicines, particularly benzodiazepines used for sleep or anxiety, and sometimes painkillers. This happened in 25 percent of the patients, and it occurred only after their symptoms had improved. This suggests that for some, medical cannabis might offer a way to simplify their medication regimen, replacing a drug that causes side effects with a treatment that manages the underlying symptom. However, the study also noted that for many others, the overall pill count remained the same, indicating that cannabis is often added to a complex regimen rather than replacing everything else.
The researchers were careful to state that because this was an observation of routine care rather than a controlled experiment, they could not prove that the cannabis caused the improvements. The patients might have gotten better for other reasons, or their symptoms might have naturally fluctuated. Yet, the consistency of the results—low doses working, symptoms easing, and serious harm remaining absent—adds a valuable piece to the puzzle. It suggests that for selected older adults under the guidance of a specialist, medical cannabis is not a risky gamble but a viable option that can be managed safely. The study reinforces a principle often used in geriatric medicine: start low and go slow. By using tiny amounts of the plant's active compounds and watching closely, doctors may be able to offer relief to a population that has long been left out of the scientific conversation.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.